MedTrace Logo

Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

NCT01322308 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-10-01

No results posted yet for this study

Summary

The present study aims to investigate the effect of pioglitazone (30 mg/day) on endothelial function in premenopausal women with SLE (systemic lupus erythematosus). Patients with hypertension, endocrine, hepatic or renal diseases will not be included, or pregnant /breast feeding women. This is a randomized, double blind, placebo controlled study.

Conditions

Interventions

DRUG

pioglitazone

30 mg tablet QD (taken once daily)

DRUG

placebo

tablet taken once a day

Sponsors & Collaborators

  • National Council of Science and Technology, Mexico

    collaborator OTHER

  • Universidad Nacional Autonoma de Mexico

    collaborator OTHER

  • National Heart Institute, Mexico

    lead OTHER_GOV

Principal Investigators

  • Carlos Posadas, MD · Head of the Endocrinology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-01-31
Completion
2012-01-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01322308 on ClinicalTrials.gov